Allarity Therapeutics (NASDAQ:ALLR) & Avenir Wellness Solutions (OTCMKTS:CURR) Head to Head Survey

Allarity Therapeutics (NASDAQ:ALLR) and Avenir Wellness Solutions (OTCMKTS:CURR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Insider and Institutional Ownership

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Avenir Wellness Solutions shares are owned by institutional investors. 0.0% of Allarity Therapeutics shares are owned by insiders. Comparatively, 17.8% of Avenir Wellness Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Allarity Therapeutics and Avenir Wellness Solutions’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	N/A	N/A	-$11.90 million	N/A	N/A
Avenir Wellness Solutions	$4.90 million	1.75	-$25.51 million	N/A	N/A

Allarity Therapeutics has higher earnings, but lower revenue than Avenir Wellness Solutions.

Volatility and Risk

Allarity Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Avenir Wellness Solutions has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

Profitability

This table compares Allarity Therapeutics and Avenir Wellness Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	N/A	-96.94%
Avenir Wellness Solutions	-477.70%	-621.61%	-65.32%

Analyst Ratings

This is a summary of recent ratings for Allarity Therapeutics and Avenir Wellness Solutions, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	0	0	0	0	N/A
Avenir Wellness Solutions	0	0	0	0	N/A

About Allarity Therapeutics

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

About Avenir Wellness Solutions

Avenir Wellness Solutions, Inc., through its subsidiary The Sera Labs, Inc., engages in the development of nutraceutical formulation and delivery technologies in novel dosage forms to improve efficacy and enhance wellness. It provides its products in beauty, health and wellness, and pet care categories under the Seratopical, Seratopical Revolution SeraLabs, and Nutri-Strips brand names. The company sells its products through drug and grocery chains, convenience stores, and mass retailers. It also offers its products under private label to retailers and multi-level marketers, as well as DTC, via online website orders. The company was formerly known as CURE Pharmaceutical Holding Corp. and changed its name to Avenir Wellness Solutions, Inc. in October 2022. Avenir Wellness Solutions, Inc. was founded in 2011 and is headquartered in Sherman Oaks, California.